Literature DB >> 17220689

The Pro12Ala polymorphism in PPARgamma2 gene affects lipid parameters in Greek primary school children: A case of gene-to-gender interaction.

George V Z Dedoussis1, Eirini V Theodoraki, Yannis Manios, Nikos Yiannakouris, Demosthenes Panagiotakos, Constantina Papoutsakis, Katerina Skenderi, Antonis Zampelas.   

Abstract

BACKGROUND: In the present study we sought to evaluate the impact of the PPAR-gamma2 Pro12Ala polymorphism on blood lipid levels of primary school children.
METHODS: 81 male and 92 female schoolchildren were genotyped. Biochemical, anthropometric, and lifestyle variables were assessed.
RESULTS: 14.1% females and 14.8% males were heterozygotes, while the rest of the subjects were homozygotes for the Pro allele. A significant interaction between the PPARgamma-2 gene and gender on blood lipid levels was detected. In particular, Pro/Pro females exhibited higher values of total cholesterol (194 +/- 32 vs 180 +/- 28 mg/dL, P = 0.06) and triglycerides (94 +/- 31 vs 77 +/- 11 mg/dL, P = 0.045) compared to Pro/Ala individuals. The gene-to-gender interaction term was highly significant (P < 0.001). On the other hand, Pro/Pro males showed higher values of HDL cholesterol (47 +/- 8 vs 43 +/- 9 mg/dL, P = 0.001), lower total cholesterol/HDL ratio (4.04 +/- 0.59 vs 4.45 +/- 0.61, P = 0.031), lower values of apoB (59.8 +/- 11.3 vs 66.8 +/- 6.6 mg/dL, P = 0.007) and lower values of apoB/apoA1 ratio (0.41 +/- 0.09 vs 0.48 +/- 0.08, P = 0.019) compared with Pro/Ala. Even after adjusting for body mass index (BMI), total energy intake, total fat intake and saturated fat intake, differences in total cholesterol/high-density lipoprotein (HDL) cholesterol and the apoB/apoA1 ratios remained significant. Regarding females, no differences were observed among genotypes concerning total cholesterol/HDL levels (P for gene-to-gender interaction = 0.001) and the apoB/apoA1 levels (P for gene-to-gender interaction = 0.029).
CONCLUSION: We show for the first time a gene-to-gender interaction on total cholesterol/HDL and apoB/apoA1 ratios, in male schoolchildren genotyped for PPAR-gamma2 Pro12Ala.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17220689     DOI: 10.1097/00000441-200701000-00002

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  5 in total

1.  G Allele of the rs1801282 Polymorphism in PPARγ Gene Confers an Increased Risk of Obesity and Hypercholesterolemia, While T Allele of the rs3856806 Polymorphism Displays a Protective Role Against Dyslipidemia: A Systematic Review and Meta-Analysis.

Authors:  Shujin Li; Chuan He; Haiyan Nie; Qianyin Pang; Ruixia Wang; Zhifu Zeng; Yongyan Song
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-29       Impact factor: 6.055

2.  Genetic variants associated with fasting blood lipids in the U.S. population: Third National Health and Nutrition Examination Survey.

Authors:  Man-huei Chang; Ajay Yesupriya; Renée M Ned; Patricia W Mueller; Nicole F Dowling
Journal:  BMC Med Genet       Date:  2010-04-20       Impact factor: 2.103

3.  Genetic influences on blood lipids and cardiovascular disease risk: tools for primary prevention.

Authors:  José M Ordovas
Journal:  Am J Clin Nutr       Date:  2009-04-01       Impact factor: 7.045

4.  Genetic variation in FADS genes and plasma cholesterol levels in 2-year-old infants: KOALA Birth Cohort Study.

Authors:  Carolina Moltó-Puigmartí; Eugène Jansen; Joachim Heinrich; Marie Standl; Ronald P Mensink; Jogchum Plat; John Penders; Monique Mommers; Gerard H Koppelman; Dirkje S Postma; Carel Thijs
Journal:  PLoS One       Date:  2013-05-08       Impact factor: 3.240

5.  Birth weight and blood lipid levels in Spanish adolescents: influence of selected APOE, APOC3 and PPARgamma2 gene polymorphisms. The AVENA Study.

Authors:  Jonatan R Ruiz; Idoia Labayen; Francisco B Ortega; Luis A Moreno; Domingo González-Lamuño; Amelia Martí; Esther Nova; Miguel García Fuentes; Carlos Redondo-Figuero; J Alfredo Martínez; Michael Sjöström; Manuel J Castillo
Journal:  BMC Med Genet       Date:  2008-11-10       Impact factor: 2.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.